论文部分内容阅读
目的:观察雷贝拉唑加莫沙必利治疗反流性食管炎的疗效。方法:将反流性食管炎110例随机分为观察组60例,对照组50例。观察组口服雷贝拉唑10mg,2次/d,对照组口服奥美拉唑20mg,2次/d。两组均同时服用莫沙必利5mg,3次/d,疗程8周。结果:治疗1周后,观察组症状缓解率93.3%,对照组78.0%,两组比较,差异显著(P<0.05);治疗8周后,两组症状缓解率、内镜下食管炎愈合率及有效率比较,差异不显著(P>0.05)。结论:雷贝拉唑治疗反流性食管炎较奥美拉唑显效快,能显著缓解其临床症状。
Objective: To observe the efficacy of rabeprazole plus mosapride in the treatment of reflux esophagitis. Methods: 110 cases of reflux esophagitis were randomly divided into observation group 60 cases, control group 50 cases. The observation group oral rabeprazole 10mg, 2 times / d, the control group omeprazole 20mg, 2 times / d. Both groups took mosapride 5mg at the same time, 3 times / d for 8 weeks. Results: After 1 week of treatment, the symptom relief rate was 93.3% in the observation group and 78.0% in the control group. There was significant difference between the two groups (P <0.05). After 8 weeks of treatment, the symptom relief rate, endoscopic esophagitis healing rate And the efficiency of comparison, the difference was not significant (P> 0.05). Conclusion: Rabeprazole is more effective than omeprazole in the treatment of reflux esophagitis, which can significantly relieve the clinical symptoms.